Quantcast
Parents Perceive Using Agave Nectar Placebo Are Better Than

Parents Perceive Using Agave Nectar, Placebo Are Better Than Doing Nothing For Cough In Kids

Provided by The JAMA Network Journals Pasteurized agave nectar and placebo were both perceived to be better by parents for treating nighttime cough and the resulting sleep difficulty in infants and toddlers than doing nothing at all, according...

Latest Bioethics Stories

2014-10-01 08:33:14

FLORHAM PARK, N.J., Oct. 1, 2014 /PRNewswire/ -- Shionogi Inc., a global leader dedicated to women's health, will unveil four abstracts containing new analyses and safety and efficacy data from clinical trials of ospemifene (available in the U.S. marketplace as Osphena(®)) at the 25(th) Annual Meeting of The North American Menopause Society (NAMS) in Washington, DC on October 15-18, 2014. Osphena(®) (ospemifene) is approved for the treatment of moderate to severe dyspareunia, a symptom of...

2014-09-27 08:21:23

- Afinitor led to an unprecedented median overall survival of 44 months, which represents a clinically meaningful while not statistically significant improvement(1) EAST HANOVER, N.J., Sept. 27, 2014 /PRNewswire/ -- Novartis today presented final results on overall survival (OS) from a Phase III trial of Afinitor(®) (everolimus) tablets plus best supportive care (BSC) compared to placebo plus BSC in patients with well-differentiated advanced and progressive pancreatic...

2014-09-24 23:03:21

New research study “Global Biopower Market - Capacity, Generation, Market Size, Major Feedstock, Regulations, and Key Country Analysis to 2025” created by GlobalData is now available at MarketPublishers.com London, UK (PRWEB) September 24, 2014 Based on cumulative capacity, the primary feedstock for biopower in mid-2014 was wood waste, which accounted for nearly 32% of total biopower capacity as it is available from a wide range of sources, e.g. timber businesses. Bagasse was the...

2014-09-17 08:29:26

- Phase 2 Clinical Results Show Positive Trends in Slowing Advancement of Disease - PALO ALTO, Calif., Sept. 17, 2014 /PRNewswire/ -- Neuraltus Pharmaceuticals, Inc. announced today that promising efficacy results of the Company's Phase 2 clinical program of NP001 for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) are being highlighted today in an oral presentation at the inaugural Summit of the ALS Research Group, being held in Bloomington,...

2014-09-08 12:20:37

Companies Combine Expertise and Resources to Advance Medical Countermeasures Development and Manufacturing ANNAPOLIS, Md. and ALACHUA, Fla., Sept. 8, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market. Under the Alliance Agreement, each company will contribute its...

2014-09-06 12:20:22

BASEL, Switzerland, September 6, 2014 /PRNewswire/ -- As one of the last airlines of its kind, Air France is ready to take on animal transports for research facilities. By doing so, Air France takes over significant responsibility for the functioning of international research, thus approving that medical progress cannot come about without experiments on animals. The Basel Declaration Society (BDS) condemns the mounting pressure on Air France from activists of animal...

2014-08-27 23:06:59

MarketOptimizer.org adds “Biopower – Global Market Size, Technology Review, Competitive Landscape, and Key Country Analysis to 2020” to its store. The report provides a clear overview of and detailed insight into the global biopower market. Dallas, Texas (PRWEB) August 27, 2014 “Biopower – Global Market Size, Technology Review, Competitive Landscape, and Key Country Analysis to 2020”, the latest report from industry analysis specialist offers comprehensive information and...

2014-08-25 08:27:22

ENGLEWOOD, Colo., Aug. 25, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is issuing this response to the most commonly asked questions in regards to the STEP study and clarify its plan for moving forward with Ampion(TM) for osteoarthritis of the knee. http://photos.prnewswire.com/prnvar/20120516/MM09116LOGO Letter to Ampio Shareholders from Michael Macaluso, Chairman & CEO and David Bar-Or, MD, Chief Scientific Officer The STEP study of Ampion(TM)...

2014-08-14 16:26:36

GREENWICH, Conn., Aug. 14, 2014 /PRNewswire/ -- Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD. In connection with the transaction, Lentigen Corporation has been renamed Opus Bio, Inc., and has been...

2014-08-11 16:28:00

Oncothyreon to Leverage Alpine's Protocell Technology to Enable Targeted Delivery of Molecular Therapeutics for Serious Diseases Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, WA, Aug. 11, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that it has acquired Alpine Biosciences, Inc., of Seattle, Washington, a privately...


Latest Bioethics Reference Libraries

OncoMouse
2013-10-02 09:29:43

The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...

More Articles (1 articles) »
Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related